Phase II trial

Alcohol use disorder
#Alcohol Use Disorder #Kinnov Therapeutics #Neuroscience #Phase II trial

Drug halves alcohol consumption to aid alcohol dependence

Kinnov Therapeutics’ Phase II study for its lead compound KT-110 has shown that the treatment can halve alcohol consumption amongst heavy drinkers in three months. The trial showed that KT-110 has superior efficacy in significantly reducing alcohol consumption in heavy drinkers by 26 to 30 grams… Read More

#News

Psilocybin
#Cybin #Depression #Major depressive disorder #Phase II trial #Psilocybin

Psychedelic antidepressant trial shows rapid and robust response

Phase II interim data for psilocybin analog CYB003 in major depressive disorder (MDD) showed rapid, robust, and clinically significant reduction of depression symptoms. Of the trial participants, 53.3% responded and 20% are in remission (i.e. no longer meeting the clinical definition of depression) after a single… Read More

#News

Kidneys
#Calliditas Therapeutics #FDA #Orphan drugs #Phase II trial

FDA orphan drug designation for Alport syndrome with setanaxib

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Calliditas Therapeutics for the treatment of Alport syndrome with setanaxib. Based on supportive pre-clinical work, Calliditas plans to initiate a randomised, placebo-controlled Phase II clinical study in Alport syndrome with around 20… Read More

#News

Covid-19 vaccines
#Covid-19 #Covid-19 vaccine #ICON #Immunology / Virology & Vaccines #Phase II trial

Partners to execute next generation Covid-19 vaccines clinical trial

ICON, a healthcare intelligence and clinical research organisation, with the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services, will execute a clinical trial to evaluate the effectiveness of next-generation Covid-19… Read More

#News

Lungs
#Antibody #Cancer research #Cancer vaccine #IO Biotech #Lung cancer #Merck #Oncology #Phase II trial

IO Biotech announces data for therapeutic cancer vaccine

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has announced data from a pre-defined interim analysis related to the lung cohort of the Phase II basket trial (IOB-022/KN-D38) with IO102-IO103 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy as… Read More

#Cancer Research #News

CT scans of the brain
#Alzheimer's #Immunotherapy #Neurodegenerative disorders #Phase II trial #Vaxxinity

Alzheimer’s immunotherapy offers safer, cheaper alternative

A new immunotherapy candidate has demonstrated a trend for slowing cognitive decline in mild Alzheimer’s disease (AD), potentially offering a more accessible and cost-effective alternative to other immunotherapies. Vaxxinity published the Phase IIa clinical trial data in The Lancet’s eBioMedicine (Volume 94, 104665, August 2023), stating… Read More

#Editor's Choice #News

Multiple myeloma
#Accelerated assessment #Bispecific Antibodies #FDA #Immunotherapy #Myeloma #Pfizer #Phase II trial

FDA accelerates approval for multiple myeloma immunotherapy

The US Food and Drug Administration (FDA) has granted accelerated approval to Pfizer’s Elrexfio (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). The drug is approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory… Read More

#News #Regulatory

Neuroblastoma
#Cancer research #Monoclonal antibodies #Neuroscience #Oncology #Phase II trial #Renaissance Pharma

Renaissance Pharma licenses Hu14.18 for neuroblastoma

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. Fifty percent of neuroblastoma patients have high-risk (HRNB) disease which has an overall survival… Read More

#Cancer Research #News

Cancer research in laboratory
#Cancer research #Oncology #Phase II trial #Promontory Therapeutics #Prostate cancer

Promontory Therapeutics expands Phase II mCRPC trial

Promontory Therapeutics has treated its first patients in France as part of the ongoing Phase II clinical trial of PT-112 in patients with late-stage metastatic castration-resistant prostate cancer (mCRPC). The Phase II proof-of-concept study has the objective of characterising the benefit-risk ratio and selecting the optimal… Read More

#Cancer Research #News

Heart attack patient with doctor
#ARMGO Pharma #Cardiovascular disease #Heart disease #Phase II trial #Rare disease

Trials of new drug for rare genetic heart disease enter Phase II

ARMGO Pharma has enrolled the first patient in a Phase II proof-of-concept clinical trial using its Rycal ARM210 (also known as S48168), for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT). The trial, performed at the Amsterdam University Medical Center (Amsterdam UMC), Netherlands and the Mayo… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trial design #Clinical trials #Oncology #Phase II trial

A third of clinical trials cancelled during Phase II

Analysis of 13,490 clinical trials finds almost a third have been cancelled during Phase II amidst an overall decline in clinical development productivity. Data analytics company Phesi has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date. Read More

#News #Trending News

#Boehringer Ingelheim #Obesity #Phase II trial #Trial data #Zealand Pharma

Patients achieve 19% weight loss in obesity drug trial

New data from Boehringer Ingelheim and Zealand Pharma has demonstrated superior efficacy with survodutide (also known as BI 456906) versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment. The findings were presented at the 2023 American Diabetes Association’s… Read More

#News

Pregnant woman in hospital
#Janssen #Phase II trial #Pregnancy #Trial data

Janssen reveals positive trial data for nipocalimab

Janssen has announced positive results from the proof-of-concept Phase II UNITY trial for the treatment of pregnant individuals at high risk of early-onset severe (EOS) haemolytic disease of the foetus and newborn (HDFN). A statistically significant (54%) proportion of participants who received nipocalimab achieved the primary… Read More

#News

Neuronal inclusions in Huntington’s disease
#Huntington's disease #Phase II trial #PTC Therapeutics #Trial data

Positive interim data for Huntington’s disease therapy

PTC Therapeutics has shared interim data from the 12-week portion of the PIVOT-HD Phase II study of PTC518 in Huntington’s disease (HD) patients. The study demonstrated dose-dependent lowering of Huntingtin (HTT) protein levels in peripheral blood cells, reaching a mean 30% reduction in mutant HTT levels… Read More

#News

Audience
#ASCO #Cancer research #Immutep #Oncology #Phase II trial

Immutep reports positive final data at ASCO 2023

Immutep revealed positive final data from Part C of the TACTI-002 Phase II trial at the ASCO 2023 Annual Meeting in Chicago, US. The trial evaluated eftilagimod alpha (efti), a soluble LAG-3 protein and first-in-class MHC Class II agonist, in combination with MSD’s (Merck) anti-PD-1 therapy Keytruda… Read More

#Cancer Research #News

Cancer research lab
#American Society of Clinical Oncology #ASCO #Cancer research #Oncology #Phase II trial #The Institute of Cancer Research #The Royal Marsden NHS Foundation Trust

New drug combination twice as effective for some ovarian cancer patients

A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a Phase II study. Researchers hope these results, which were presented at the 2023 American Society of Clinical… Read More

#Cancer Research #News